The research carried out by the Vaccines and Immune Response to Infections Unit is channelled through the Barcelona Institute for Global Health (ISGlobal) and the August Pi Sunyer Biomedical Research Institute (IDIBAPS).

The unit has created a comprehensive platform for clinical trials of vaccines for the evaluation of new vaccine candidates or new indications for existing vaccines, mainly through phases II, III and IV, including trials of vaccines recommended for our environment, vaccines for international travellers or vaccines related to global health. Likewise, the Unit’s Microbiology and Immunology services evaluate the humoral and cellular response of vaccine candidates at different phases of clinical development and investigate different biomarkers involved in the generation of adverse reactions, especially immune-mediated ones.

The members of the Unit also carry out studies on vaccine coverage in different groups (vulnerable population, people with risk factors, travellers), immunogenicity, adverse reactions, pharmacovigilance and the monitoring of virus-specific T-cell responses in immunocompromised patients (solid organ transplant recipients, haematopoietic stem cell transplant recipients, and CAR T-cell therapy recipients).